International scientific guideline: Octreotide acetate depot powder and solvent for suspension for injection 10mg, 20mg or 30mg product - specific bioequivalence guidance

About this guideline

TGA adopted date: 15 Jul 2019

Overseas effective date: 1 Aug 2019

Categories: Clinical efficacy and safety | Clinical pharmacology and pharmacokinetics | Product-specific bioequivalence

Access this international scientific guideline

For more information see International scientific guidelines adopted in Australia.

Where EU guidelines adopted in Australia include references to EU legislation (including EC Directives and Regulations), the requirements contained in the referenced EU legislation are not applicable to the evaluation of medicines by the TGA.